Slide 1: Q2'24 Earnings Presentation
Enabling discovery, safety and production of tomorrow’s therapeutics NASDAQ: HBIO Q2’24 Earnings Presentation Jim Green, Chairman, President & CEO Jennifer Cote, CFO & Treasurer August 8, 2024
Slide 2: Forward-Looking Statements and Non-GAAP Financial Information
Forward-Looking Statements and Non-GAAP Financial Information Forward-Looking Statements This document contains forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified b
Slide 3: CEO Summary: Q2'24 Highlights
CEO Summary: Q2’24 Highlights Stay the course, stay lean and remain focused on product commercializations for new revenue streams Income Statement Components ($ in millions except percentages) Q2' 2024 Q2'2023 Revenue 23.1 28.8 Gross Margin 13.2 16.7 % of Revenue 57.2% 58.0% Operating (Loss) Income
Slide 4: Q2'24 Revenue by Geography
Q2’24 Revenue by Geography Fx Adjustment (in $M) Q1'24 Q2'24 Q2'23 vs Q1 vs PY As Reported CMT $ 11.0 $ 11.7 $ 13.5 7% (13%) Pre-Clinical $ 13.5 $ 11.4 $ 15.3 (16%) (25%) Currency* $ 0.0 $ (0.0) Total $ 24.5 $ 23.1 $ 28.8 (6%) (20%) Americas EMEA APAC • Overall: Down 12% as reported from prior year,
Slide 5: Q2'24 Financial Metrics (GAAP except where noted)
Q2’24 Financial Metrics (GAAP except where noted) $ Million except REVENUE ADJUSTED EBITDA* per share data GROSS MARGIN $3.9 $1.3 (LOSS) EARNINGS PER SHARE CASH FLOW FROM OPERATIONS NET DEBT* GAAP Adjusted* Q2’24 Q2’23 Q2’24 Q2’23 Q2’ YTD 24 Q2’ YTD 23 Q2’ 24 Q4’23 * Non-GAAP measure, reconciliation
Slide 6: New Product Introductions: Focused on Commercialization
New Product Introductions: Focused on Commercialization EXPAND HIGH GROWTH EXPAND HIGH GROWTH STRENGTHEN THE BASE: TARGET > MARKET GROWTH BIO-PRODUCTION MESH ORGANOID PRECLINICAL CMT CMT- ORGANOIDS • Ponemah Enterprise Data Acquisition/Analysis GLP • Established BTX brand for • Introduced breakthrou
Slide 7: 2024 New Product Introductions: Supports Long Term Growth Targets
2024 New Product Introductions: Supports Long Term Growth Targets Growth Category Product Line Application Customers Commercial Status Key Trade Show Product Focus • Federation of European Neuroscience Societies • CROs • Q3: Soho Production • SoHo Shared • Safety Shipments • Safety Pharmacology Soci
Slide 8: Outlook
8 Outlook 8
Slide 9: 2024 Full Year Outlook
2024 Full Year Outlook For FY2024, we expect: ▪ With a weaker than planned Q2 and a market recovery pushing to late 2024, we are reducing our revenue outlook for the year to be $97M-$102M ▪ Sequential growth in the second half primarily supported by new product commercializations ▪ Gross Margins to
Slide 10: Appendix
10 Appendix 10
Slide 11: Reconciliation to GAAP P&L
Reconciliation to GAAP P&L (1) Other operating expenses for the three months ended June 30, 2024 include a credit of $(0.1) million related to an unclaimed property audit and $0.4 million of restructuring-related charges. Other operating expenses for the six months ended June 30, 2024 include a $0.5
Slide 12: Slide 12